Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its programs include RELVAR or BREO (fluticasone furoate/vilanterol), ANORO (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid Receptor Antagonist program. Fluticasone Furoate/Vilanterol (FF/VI) is an investigational once-daily inhaled ICS/ LABA combination treatment, comprising fluticasone furoate (FF) and vilanterol (VI), for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) and patients with asthma.
|Headquarters||901 Gateway Boulevard|
SOUTH SAN FRANCISCO, CA, United States 94080
|Chairman of the Board, Chief Executive Officer||Rick Winningham|
|Chief Financial Officer, Senior Vice President||Michael Aguiar|
|Senior Vice President, General Counsel, Secretary||Bradford Shafer|
|Chief Commercial Officer, Senior Vice President||Leonard Blum|
|Senior Vice President - Research & Early Clinical Development||Mathai Mammen|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||99.5M||Book Value||$1.58|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||373.0|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-1,323.86%|
*GAAP = prior to non-GAAP analyst adjusted earnings.